Home > Gastroenterology > UEGW 2020 > UEGW Round-Up Articles > Dupilumab improves in diverse aspects of eosinophilic oesophagitis

Dupilumab improves in diverse aspects of eosinophilic oesophagitis

Presented By
Prof. Evan S. Dellon, University of North Carolina School of Medicine, USA
Conference
UEGW 2020
Trial
Phase 3
  Weekly dupilumab demonstrated significant and clinically meaningful improvements in histologic, symptomatic, endoscopic, and molecular aspects of eosinophilic oesophagitis (EoE). In addition, dupilumab was well tolerated. That was found in part A of an ongoing 3-part, randomised, placebo-controlled, phase 3 study [1]. EoE is a chronic type 2 inflammatory disease of the oesophagus that can substantially impair the quality of life. Only a few treatment options are currently available and the response to the current therapy is generally suboptimal. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin (IL)-4 and IL-13. These cytokines are key drivers of type 2 inflammation in EoE. In a previous phase 2 proof-of-concept study, dupilumab significantly improved histological and clinical ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on